 Cardiovascular Systems Inc NASDAQ: CSII has announced the development of intravascular lithotripsy IVL technology for coronary and peripheral artery diseases. Enrolling patients in an investigational device exemption study for the CSI coronary IVL system is currently targeted for calendar 2023. 